Companion diagnostics and personalized medicine are no longer theory but rather near future if not reality of today’s therapeutic approaches to treat cardiovascular and neurological diseases as well as cancer, to name only some clinical areas.
The approach is to bring new drugs along with supporting tests to the market that will help physicians make the decision for a specific drug prescription at a specific dose and help to evaluate potential side effects on a patient to patient basis.
A growing understanding of disease underlying biological processes and increased opportunities in disease evaluation at the molecular level by biomarkers, allows pharmaceutical and diagnostic companies nowadays to characterize patients and disease and predict disease outcome and assess disease prognosis better.
We have invited speakers from pharmaceutical as well as molecular diagnostic companies to provide you with expert insight into the area of personalized medicine and biomarkers for companion diagnostics.
Topics for discussion after the panel talks will include:
- What can and what can’t be done by personalized medicine? ·
- What are biomarkers and how are they used in disease prediction and prognosis?
- How can biomarkers help in assessing how far a disease has already progressed (disease staging ) e.g. in diseases like cancer?
- What is the promise genomic and proteomic approaches hold for personalized medicine?
- What are potential risks of personalized medicine?
- What are the socio-political consequences of personalized medicine?
Panel:
Agenda:
- 6:00 - 7:00 pm Registration / Networking
- 7:00 - 8:30 pm Program
- 8:30 - 9:00 pm Networking / Reception
Complimentary appetizers, beer, wine and soft drinks will be served.
Location:
Therevance, 901 Gateway Blvd., South San Francisco, CA 94080, Local: 650-808-6000
Cost: $20 Members, $35 Non-Members, $50 at the door
RSVP: To RSVP, register and pay please use the link below!
